Table 2.
Overview of clinical characteristics per patient
| Patient | Age | Disease duration (years) | LEDD (mg) | Parkinson-medication | Time to scan since medication (h) | UPDRS III (before scan) | Duration of pain (years) | Wearing-offa | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Levodopa | DA-agonist | Other | OFF | ON | OFF | ON | ||||||
| #1 | 55 | 3.5 | 564 | Yes | 15.0 | 1.0 | 24 | 18.5 | 3.00 | Yes | ||
| #2 | 73 | 2.0 | 752 | Yes | 17.0 | 1.0 | 28 | 20 | 8.00 | Yes | ||
| #3 | 67 | 10.0 | 564 | Yes | 20.5 | 1.0 | 20 | 17 | 30.00 | Yes | ||
| #4 | 72 | 3.0 | 375 | Yes | 16.5 | 1.5 | 14 | 17 | 3.00 | Yes | ||
| #5 | 68 | 1.0 | 828 | Yes | 16.0 | 2.5 | 16 | 11 | 0.00 | No | ||
| #6 | 56 | 2.0 | 375 | Yes | 26.5 | 2.0 | 11 | 7 | 1.00 | No | ||
| #7 | 68 | 2.0 | 378 | Yes | 19.5 | 5.5 | 13 | 13 | 0.00 | Yes | ||
| #8 | 65 | 8.0 | 850 | Yes | MAO-B inhibitor (rasagiline), COMT inhibitor (entacapone) | 12.5 | 1.5 | 18 | Missing | 1.00 | Yes | |
| #9 | 62 | 4.0 | 2780 | Yes | COMT inhibitor (entacapone) | 14.5 | 3.0 | 33 | 18 | 3.00 | No | |
| #10 | 64 | 5.5 | 982 | Yes | DA-agonist (pramipexol) | 14.5 | 2.0 | 25 | 30 | 0.25 | No | |
| #11 | 68 | 2.0 | 125 | Yes | 15.5 | 2.5 | 6 | 7 | 3.00 | No | ||
| #12 | 69 | 1.0 | 500 | Yes | 15.0 | 8.0 | 19 | 19 | 0.00 | No | ||
| #13 | 73 | 5.0 | 375 | Yes | 13.5 | 3.5 | 37 | 32 | 5.00 | Yes | ||
| #14 | 70 | 3.0 | 1548 | Yes | COMT inhibitor (entacapone) | 15.5 | 1.5 | 17 | 19 | 5.00 | Yes | |
| #15 | 71 | 6.0 | 1038 | Yes | DA-agonist (pramipexol) | 8.5 | 5.5 | 35 | 31 | 7.00 | Yes | |
| #16 | 47 | 6.0 | 1428 | Yes | DA-agonist (ropinirol) | 14.0 | 1.0 | 24 | 9 | 0.00 | No | |
| #17 | 48 | 0.5 | 1000 | Yes | 15.0 | 1.5 | 6 | 5 | 0.00 | Yes | ||
| #18 | 56 | 6.0 | 935 | Yes | DA-agonist (pramipexol) | MAO-B inhibitor (rasagiline) | 13.0 | 1.5 | 31 | 13 | 2.00 | Yes |
| #19 | 66 | 1.0 | 90 | Yes | 16.5 | 2.0 | 26 | 26 | 5.00 | No | ||
| #20 | 53 | 5.0 | 615 | Yes | DA-agonist (ropinirol) | 19.5 | 1.5 | 22 | 18 | 7.00 | Yes | |
| #21 | 72 | 13.0 | 1150 | Yes | DA-agonist (pramipexol) | MAO-B inhibitor (rasagiline) | 16.0 | 2.0 | 23 | 26 | 0.00 | No |
| #22 | 57 | 1.0 | 106 | No | DA-agonist (pramipexol) | 18.5 | 4.5 | 18 | 12 | 2.00 | Yes | |
| #23 | 51 | 6.0 | 1645 | Yes | DA-agonist (ropinirol) | Amantadine | 14.0 | 2.5 | 25 | 16 | 5.00 | No |
| #24 | 61 | 1.5 | 108 | No | DA-agonist (pramipexol) | 27.0 | 12.0 | 15 | 22 | 0.75 | Yes | |
aWearing off was determined as having 2 or more symptoms that improved with medication-intake, based on (Martinez-Martin and Hernandez 2012). One patient took a combination of an NSAID (Ibuprofen) and acetaminophen on a daily basis, all other patients did not any have pharmacological intervention for their pain